PolyPid Ltd. announced on September 30, 2025, that Dr. Shmuel Sharoni will present the topline results from the successful Phase 3 SHIELD II trial of D-PLEX100 at the 2025 American College of Surgeons (ACS) Clinical Congress. The presentation is scheduled for Sunday, October 5, 2025, in Chicago, IL.
The presentation, titled 'Efficacy Of A Novel Local Prolonged-release Incisional Doxycycline On Surgical Site Infection Prophylaxis In Abdominal Colorectal Surgery: The Shield II Phase 3 Randomized Clinical Trial,' will be part of the high-impact clinical trials session.
The SHIELD II trial successfully met its primary and all key secondary efficacy endpoints, demonstrating a 38% reduction (p<0.005) in the combined endpoint of surgical site infections, reinterventions, or mortality. Additionally, the trial showed a 58% reduction (p<0.005) in the rate of surgical site infections in the D-PLEX100 treatment arm.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.